Experimental Drug Shows Promise Against Pre-Cancerous Blood Disorder
What Happened
A clinical trial found that teclistamab, an immunotherapy drug already approved for difficult-to-treat multiple myeloma, cleared disease markers in 78% of patients with high-risk smoldering multiple myeloma, a pre-cancerous bone marrow disorder that can progress to blood cancer. Researchers tested the drug earlier in the disease course and observed strong responses among patients, suggesting it may help delay or prevent the development of full-blown multiple myeloma.
Key Takeaways
The findings raise hopes that treating high-risk patients before cancer develops could improve outcomes and reduce future disease progression. However, larger studies will be needed before the approach becomes a standard treatment option. Teclistamab is already approved in the US and Europe for patients with relapsed or treatment-resistant multiple myeloma.